Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study

OBJECTIVE: DS-8500a is a novel G protein-coupled receptor 119 agonist being developed for the treatment of type 2 diabetes. The study objective was to assess the efficacy and safety of DS-8500a in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this double-blind, parallel-gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, Nobuya, Chou, Hubert S, Tsukiyama, Shuji, Washio, Takuo, Shiosakai, Kazuhito, Nakatsuka, Yasuhiko, Taguchi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640040/
https://www.ncbi.nlm.nih.gov/pubmed/29071087
http://dx.doi.org/10.1136/bmjdrc-2017-000424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640040/
https://www.ncbi.nlm.nih.gov/pubmed/29071087
http://dx.doi.org/10.1136/bmjdrc-2017-000424

Ejemplares similares